White Oak, Md., April 24, 2026 (GLOBE NEWSWIRE) — The U.S. Meals and Drug Administration immediately authorized Otarmeni (lunsotogene parvec-cwha), the first-ever twin adeno-associated virus (AAV) vector-based gene remedy. Otarmeni is indicated for the remedy of pediatric and grownup sufferers with severe-to-profound and profound sensorineural listening to loss (any frequency >90 dB HL) related to molecularly confirmed biallelic variants within the OTOF gene.
Previous to immediately’s approval, no illness modifying remedies existed for OTOF-related deafness. Otarmeni is for sufferers with preserved outer hair cell perform and no prior cochlear implant in the identical ear.
“Today’s approval is a significant milestone in the treatment of genetic hearing loss,” mentioned FDA Commissioner Marty Makary, M.D., M.P.H. “Through the national priority voucher pilot program, the agency is accelerating therapies for rare diseases with unmet medical needs while proving we can successfully review even the most complex submissions—such as novel dual vector gene therapies and combination products requiring coordination across multiple offices and centers—in significantly shortened timeframes.”
Genetic mutations trigger about half of congenital listening to loss. Variants within the OTOF gene account for two% to eight% of inherited, non-syndromic instances. Sufferers with two nonworking copies don’t produce otoferlin, disrupting sound sign transmission. Delayed prognosis can result in missed remedy home windows and lasting speech and language delays.
Otarmeni and the administration equipment are a one time biologic-device mixture product. It features a twin adeno-associated virus serotype 1 (AAV1) vector gene remedy administered as a single dose per ear surgically into the cochlea by way of a syringe and catheter supplied within the Administration Equipment and related to an infusion pump. Otarmeni delivers a purposeful copy of the OTOF gene to interior hair cells to revive otoferlin manufacturing and auditory signaling.
More Read
The security and effectiveness of Otarmeni have been based mostly on outcomes from a single, ongoing, multi-center, single-arm (in comparison with the pure historical past of untreated HL) medical trial in 24 pediatric sufferers aged 10 months to 16 years with OTOF gene-associated severe-to-profound and profound sensorineural listening to loss (any frequency >90 dB HL) with confirmatory proof together with mechanistic nonclinical knowledge and sustained otoferlin protein expression post-Otarmeni administration. Of the 20 sufferers who have been evaluable for efficacy, 80% skilled improved listening to, which isn’t anticipated within the pure historical past of the illness with out intervention.
Widespread uncomfortable side effects included center ear an infection, nausea, dizziness, and procedural ache. Suppliers ought to monitor for surgical issues. The remedy just isn’t beneficial for sufferers with anatomy that stops secure entry to the interior ear.The applying was granted orphan drug, uncommon pediatric illness, quick observe, and regenerative drugs superior remedy (RMAT) designations. The FDA granted accelerated approval of Otarmeni to Regeneron Prescription drugs, Inc. Continued approval could also be contingent upon evaluation of sturdiness of listening to enchancment together with verification of remedy results on medical measures of speech improvement and high quality of life.
On June 4, 2026, the FDA will host a public assembly to solicit suggestions in regards to the CNPV pilot program’s eligibility standards, the voucher choice course of, sponsor’s obligations, pre-submission necessities, FDA evaluate procedures, the function of the CNPV evaluate council, and program implementation. events may submit written feedback by means of June 29, 2026.
More Read
###
The FDA, an company inside the U.S. Division of Well being and Human Providers, protects the general public well being by assuring the protection, effectiveness, and safety of human and veterinary medicine, vaccines and different organic merchandise for human use, and medical gadgets. The company is also liable for the protection and safety of our nation’s meals provide, cosmetics, dietary dietary supplements, radiation-emitting digital merchandise, and for regulating tobacco merchandise.
Contact Data
